Published in
Elsevier, European Urology, 3(67), p. 496-503
DOI: 10.1016/j.eururo.2014.08.007
Links
Tools
Patient-derived Xenografts Reveal that Intraductal Carcinoma of the Prostate Is a Prominent Pathology in BRCA2 Mutation Carriers with Prostate Cancer and Correlates with Poor Prognosis
Journal article published in 2015 by
Gail P. Risbridger,
Renea A. Taylor,
David Clouston,
Ania Sliwinski,
Heather Thorne 
,
Sally Hunter,
Jason Li,
Gillian Mitchell,
Declan Murphy,
Mark Frydenberg,
David Pook,
John Pedersen,
Roxanne Toivanen,
Hong Wang,
Melissa Papargiris
and other authors.
,
Sally Hunter,
Jason Li,
Gillian Mitchell,
Declan Murphy,
Mark Frydenberg,
David Pook,
John Pedersen,
Roxanne Toivanen,
Hong Wang,
Melissa Papargiris
and other authors.
This paper is available in a repository.
Full text: Download
Published version:
archiving forbidden
Data provided by 
Abstract
Intraductal carcinoma of the prostate (IDC-P) is a distinct clinicopathologic entity associated with aggressive prostate cancer (PCa). PCa patients carrying a breast cancer 2, early onset (BRCA2) germline mutation exhibit highly aggressive tumours with poor prognosis.